Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 82

1.

Response to third rubella vaccine dose.

Siira L, Nøkleby H, Barlinn R, Riise ØR, Aaberge IS, Dudman SG.

Hum Vaccin Immunother. 2018;14(10):2472-2477. doi: 10.1080/21645515.2018.1475814. Epub 2018 Jun 21.

PMID:
29771601
2.

In vitro and in vivo comparison of transport media for detecting nasopharyngeal carriage of Streptococcus pneumoniae.

Steens A, Milhano N, Aaberge IS, Vestrheim DF.

PeerJ. 2016 Sep 22;4:e2449. doi: 10.7717/peerj.2449. eCollection 2016.

3.

Validate or falsify: Lessons learned from a microscopy method claimed to be useful for detecting Borrelia and Babesia organisms in human blood.

Aase A, Hajdusek O, Øines Ø, Quarsten H, Wilhelmsson P, Herstad TK, Kjelland V, Sima R, Jalovecka M, Lindgren PE, Aaberge IS.

Infect Dis (Lond). 2016;48(6):411-9. doi: 10.3109/23744235.2016.1144931. Epub 2016 Feb 23.

PMID:
27030913
4.

Geographical differences in seroprevalence of Borrelia burgdorferi antibodies in Norway, 2011-2013.

Vestrheim DF, White RA, Aaberge IS, Aase A.

Ticks Tick Borne Dis. 2016 Jul;7(5):698-702. doi: 10.1016/j.ttbdis.2016.02.020. Epub 2016 Feb 27.

PMID:
26961275
5.

Tetanus after a minor injury leading to death in a previously non-immunized, elderly, Norwegian woman.

Brandsæter B, Aaberge IS, Dunlop O.

IDCases. 2015 Apr 2;2(2):53-5. doi: 10.1016/j.idcr.2015.03.003. eCollection 2015.

6.

Decreased Carriage and Genetic Shifts in the Streptococcus pneumoniae Population After Changing the Seven-valent to the Thirteen-valent Pneumococcal Vaccine in Norway.

Steens A, Caugant DA, Aaberge IS, Vestrheim DF.

Pediatr Infect Dis J. 2015 Aug;34(8):875-83. doi: 10.1097/INF.0000000000000751.

PMID:
26020410
7.

Characterization of the extent of a large outbreak of Legionnaires' disease by serological assays.

Simonsen Ø, Wedege E, Kanestrøm A, Bolstad K, Aaberge IS, Ragnhildstveit E, Ringstad J.

BMC Infect Dis. 2015 Mar 28;15:163. doi: 10.1186/s12879-015-0903-2.

8.

A review of the evidence to inform pneumococcal vaccine recommendations for risk groups aged 2 years and older.

Steens A, Vestrheim DF, Aaberge IS, Wiklund BS, Storsaeter J, Riise Bergsaker MA, Rønning K, Furuseth E.

Epidemiol Infect. 2014 Dec;142(12):2471-82. doi: 10.1017/S0950268814001514. Epub 2014 Jun 16. Review.

PMID:
24932959
9.

Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.

Steens A, Bergsaker MA, Aaberge IS, Rønning K, Vestrheim DF.

Vaccine. 2013 Dec 16;31(52):6232-8. doi: 10.1016/j.vaccine.2013.10.032. Epub 2013 Oct 29.

PMID:
24176490
10.

Human antibody responses to pneumococcal surface protein A and capsular polysaccharides during acute and convalescent stages of invasive disease in adult patients.

Kolberg J, Aase A, Naess LM, Aaberge IS, Caugant DA.

Pathog Dis. 2014 Feb;70(1):40-50. doi: 10.1111/2049-632X.12106. Epub 2013 Nov 21.

PMID:
24151210
11.

Legionella bacteria in water supply systems.

Aaberge IS.

Tidsskr Nor Laegeforen. 2013 Aug 6;133(14):1426. doi: 10.4045/tidsskr.13.0762. English, Norwegian. No abstract available.

12.

Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future.

Holst J, Oster P, Arnold R, Tatley MV, Næss LM, Aaberge IS, Galloway Y, McNicholas A, O'Hallahan J, Rosenqvist E, Black S.

Hum Vaccin Immunother. 2013 Jun;9(6):1241-53. doi: 10.4161/hv.24129. Epub 2013 Mar 7. Review.

13.

Pectic polysaccharides isolated from Malian medicinal plants protect against Streptococcus pneumoniae in a mouse pneumococcal infection model.

Inngjerdingen KT, Langerud BK, Rasmussen H, Olsen TK, Austarheim I, Grønhaug TE, Aaberge IS, Diallo D, Paulsen BS, Michaelsen TE.

Scand J Immunol. 2013 May;77(5):372-88. doi: 10.1111/sji.12047.

14.

Pre-natal exposure to perfluoroalkyl substances may be associated with altered vaccine antibody levels and immune-related health outcomes in early childhood.

Granum B, Haug LS, Namork E, Stølevik SB, Thomsen C, Aaberge IS, van Loveren H, Løvik M, Nygaard UC.

J Immunotoxicol. 2013 Oct-Dec;10(4):373-9. doi: 10.3109/1547691X.2012.755580. Epub 2013 Jan 25.

PMID:
23350954
15.

Preserved function after angioembolisation of splenic injury in children and adolescents: a case control study.

Skattum J, Loekke RJ, Titze TL, Bechensteen AG, Aaberge IS, Osnes LT, Heier HE, Gaarder C, Naess PA.

Injury. 2014 Jan;45(1):156-9. doi: 10.1016/j.injury.2012.10.036. Epub 2012 Dec 14.

PMID:
23246563
16.

Decline in early childhood respiratory tract infections in the Norwegian mother and child cohort study after introduction of pneumococcal conjugate vaccination.

Magnus MC, Vestrheim DF, Nystad W, Håberg SE, Stigum H, London SJ, Bergsaker MA, Caugant DA, Aaberge IS, Nafstad P.

Pediatr Infect Dis J. 2012 Sep;31(9):951-5.

17.

Postvaccination increase in serotype 19A pneumococcal disease in Norway is driven by expansion of penicillin-susceptible strains of the ST199 complex.

Vestrheim DF, Steinbakk M, Aaberge IS, Caugant DA.

Clin Vaccine Immunol. 2012 Mar;19(3):443-5. doi: 10.1128/CVI.05563-11. Epub 2012 Jan 11.

18.

Pherotypes of pneumococcal strains co-existing in healthy children.

Vestrheim DF, Gaustad P, Aaberge IS, Caugant DA.

Infect Genet Evol. 2011 Oct;11(7):1703-8. doi: 10.1016/j.meegid.2011.07.003. Epub 2011 Jul 7.

PMID:
21763465
19.

Immunization of teenagers with a fifth dose of reduced DTaP-IPV induces high levels of pertussis antibodies with a significant increase in opsonophagocytic activity.

Aase A, Herstad TK, Merino S, Bolstad M, Sandbu S, Bakke H, Aaberge IS.

Clin Vaccine Immunol. 2011 Aug;18(8):1269-74. doi: 10.1128/CVI.05067-11. Epub 2011 Jun 15.

20.

An exploratory trial of cyclooxygenase type 2 inhibitor in HIV-1 infection: downregulated immune activation and improved T cell-dependent vaccine responses.

Pettersen FO, Torheim EA, Dahm AE, Aaberge IS, Lind A, Holm M, Aandahl EM, Sandset PM, Taskén K, Kvale D.

J Virol. 2011 Jul;85(13):6557-66. doi: 10.1128/JVI.00073-11. Epub 2011 Apr 13.

Supplemental Content

Loading ...
Support Center